share_log

Oppenheimer Initiates Coverage On Clarus Therapeutics Hldgs with Outperform Rating, Announces Price Target of $12

Benzinga Real-time News ·  Sep 20, 2021 08:19

Oppenheimer analyst Leland Gershell initiates coverage on Clarus Therapeutics Hldgs (NASDAQ:CRXT) with a Outperform rating and announces Price Target of $12.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment